Articles

Author: Mary Hulihan, DrPH Hello. I am Dr Mary Hulihan, a health scientist in the Division of Blood Disorders at the Centers for Disease Control and Prevention. Today I would like to talk about the indications for blood transfusion in patients with sickle cell disease, the complications associated with these transfusions, and how you can help

Maurie Markman, MD Hello. I am Dr Maurie Markman from Cancer Treatment Centers of America in Philadelphia, Pennsylvania. I wanted to briefly highlight the recently updated US Food and Drug Administration (FDA) assessment on the use of laparoscopic power morcellators to treat uterine fibroids. This is clearly a complex and controversial topic, and one that

Anya Romanowski, MS, RD The Role of Gender and Perception in Surgical Specialty Choice In the United States and abroad, there is a growing public reckoning over the routine discrimination and harassment that many women have faced in the workplace. The field of surgery has not been immune to these larger upheavals. Although surgery remains

JoAnn E. Manson, MD, DrPH Dr JoAnn Manson, professor of medicine at Harvard Medical School and Brigham and Women’s Hospital in Boston, Massachusetts. I’d like to talk with you today about vitamin and mineral supplements. Is there a rational approach? Most of our patients are taking dietary supplements, usually vitamin or mineral supplements, and we

Author: Charles P. Vega, MD; Temitayo A. Ogunleye, MD Clinicians see many skin conditions in the primary care setting. Medscape talked with a primary care clinician, Charles P. Vega, MD, and a dermatologist, Temitayo A. Ogunleye, MD, to learn their thoughts on how to best diagnose and manage dermatology-related symptoms in primary care. This consultation is

Author: David J. Kerr, CBE, MD, DSc, FRCP, FMedSci Hello. I am David Kerr, professor of cancer medicine from the University of Oxford, England. I want to talk about an interesting paper I picked up recently in Annals of Oncology.[1] This was prepared and presented by Dr Aggarwal from Richard Sullivan’s group at Kings College London. They have done a lot

Author:  Harmeet Kaur Bhatia, Harmanjit Singh,1 Nipunjot Grewal,2 and Navreet Kaur Natt3 Abstract Hepatitis C currently infects more than 170 million people around the world, leading to significant morbidity and mortality. The current standard of care for HCV infection, including one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 weeks, along with pegylated